Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1945]

Nivolumab with alternatively scheduled ipilimumab in first-line treatment of...

Dr Naveen Vasudev - Leeds Cancer Centre, Leeds, UK

Nivolumab with alternatively scheduled ipilimumab in first-line treatment of advanced RCC ( Dr Naveen Vasudev - Leeds Cancer Centre, Leeds, UK )

KEYNOTE-355: First-line pembrolizumab plus chemotherapy for metastatic triple...

Prof Hope Rugo - University of California San Francisco, San Francisco, USA

KEYNOTE-355: First-line pembrolizumab plus chemotherapy for metastatic triple-negative breast cancer ( Prof Hope Rugo - University of California San Francisco, San Francisco, USA )

High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally...

Dr Jeroen Van Dorp - Netherlands Cancer Institute, Amsterdam, The Netherlands

High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advanced urothelial cancer ( Dr Jeroen Van Dorp - Netherlands Cancer Institute, Amsterdam, The Netherlands )

KEYNOTE-716: Adjuvant pembrolizumab prolongs recurrence-free survival in...

Dr Jason Luke - UPMC Hillman Cancer Center, Pittsburgh, USA

KEYNOTE-716: Adjuvant pembrolizumab prolongs recurrence-free survival in resected stage II melanoma ( Dr Jason Luke - UPMC Hillman Cancer Center, Pittsburgh, USA )

Immunotherapy prolongs survival in recurrent, persistent or metastatic cervical...

Prof Bradley Monk - University of Arizona College of Medicine, Phoenix, USA

Immunotherapy prolongs survival in recurrent, persistent or metastatic cervical cancer ( Prof Bradley Monk - University of Arizona College of Medicine, Phoenix, USA )

OncoAlert and ecancer - ESMO 2021 Day 2

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer - ESMO 2021 Day 2 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

ESMO President: What to watch for at ESMO 2021

Prof Solange Peters - ESMO President

ESMO President: What to watch for at ESMO 2021 ( Prof Solange Peters - ESMO President )

Nivolumab plus ipilimumab shows benefit over chemo for unresectable malignant...

Prof Solange Peters - Lausanne University Hospital, Lausanne, Switzerland

Nivolumab plus ipilimumab shows benefit over chemo for unresectable malignant pleural mesothelioma ( Prof Solange Peters - Lausanne University Hospital, Lausanne, Switzerland )

Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA...

Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City...

$Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T therapy ( Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City, USA )$

Idecabtagene vicleucel for relapsed and refractory multiple myeloma

Prof Larry Anderson - UT Southwestern Medical Center, Dallas, USA

$Idecabtagene vicleucel for relapsed and refractory multiple myeloma ( Prof Larry Anderson - UT Southwestern Medical Center, Dallas, USA )$

OncoAlert and ecancer weekly round up for August 2 - August 14, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly round up for August 2 - August 14, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

OncoAlert and ecancer weekly round up for July 26 - August 1, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly round up for July 26 - August 1, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

More from ecancer